An advisory committee to the US Food and Drug Administration (FDA) voted 8-6 with one abstention on Thursday to recommend that two peptides BPC-157 to treat ulcerative colitis and KPV for wound treatment and inflammatory conditions be added to the list of drugs eligible for bulk compounding, known as the 503A Bulks List
(Watermelon, Strawberry and Berry Mint Flavors)
Is the cause or etiology stated
Studies suggest similar speeds, but BPC-157 might produce stronger healed tissue
Features: Features: Unique quick action formula Safe and effective Precise pH value Applications: Applications: Prescribed for treating obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis Composition: Each 0.5 ml contains Phytomenadione BP 1 mg Water for Injection BP q.s Indication: Phytomenadione Injection is indicated in Anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives Prophylaxis and therapy of hemorrhagic disease of the newborn Hypoprothrombinemia due to antibacterial therapy Hypoprothrombinemia secondary to factors limiting absorption or synthesis of Phytomenadione, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with Phytomenadione metabolism, e.g., salicylates Presentation: 10 x 1ml Ampoule Additional Information: Packaging Details: 10 x 0.5 ml Ampoules in printed carton with pack insert
The main caution is additive glucose-lowering effects if you're also on insulin or other hypoglycemic agents, which could risk low blood sugar
